Wall Street analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) to announce ($0.39) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aldeyra Therapeutics’ earnings. Aldeyra Therapeutics reported earnings per share of ($0.35) during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.4%. The company is expected to announce its next quarterly earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.66) per share for the current fiscal year, with EPS estimates ranging from ($1.79) to ($1.52). For the next financial year, analysts forecast that the business will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.64) to ($1.37). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06).
ALDX has been the subject of several recent analyst reports. Cantor Fitzgerald set a $23.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 15th. ValuEngine raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Canaccord Genuity reissued a “buy” rating and set a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Seaport Global Securities reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Thursday, March 1st. Finally, Zacks Investment Research raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 21st. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.08.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Element Capital Management LLC acquired a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $123,000. Northern Trust Corp increased its stake in shares of Aldeyra Therapeutics by 34.3% in the first quarter. Northern Trust Corp now owns 48,151 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 12,290 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Aldeyra Therapeutics by 19.8% in the first quarter. JPMorgan Chase & Co. now owns 59,502 shares of the biotechnology company’s stock valued at $446,000 after buying an additional 9,826 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Aldeyra Therapeutics by 22.6% in the first quarter. Dimensional Fund Advisors LP now owns 62,429 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 11,506 shares during the period. Finally, Stanley Laman Group Ltd. acquired a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $480,000. 51.17% of the stock is owned by hedge funds and other institutional investors.
ALDX traded down $0.05 on Friday, hitting $8.45. 100 shares of the stock were exchanged, compared to its average volume of 86,108. Aldeyra Therapeutics has a 12 month low of $3.90 and a 12 month high of $11.90. The company has a quick ratio of 11.09, a current ratio of 11.09 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $169.92 million, a price-to-earnings ratio of -6.00 and a beta of 0.57.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.